Press releases
US-specific press releases are available here. Please visit our global website for access to global press releases dating back to 2009.
-
GSK completes acquisition of Sierra Oncology
GSK announced it has completed the acquisition of Sierra Oncology, a California-based biopharmaceutical company.
Read more -
GSK selects Target the Future grant recipient in innovation challenge supporting multiple myeloma community
Target the Future is an initiative dedicated to advancing innovation and addressing key needs in the multiple myeloma community.
Read more -
Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine
First ever reported efficacy data in an Omicron environment support relevance of a Beta-containing vaccine
Read more -
GSK announces positive pivotal phase III data for its respiratory syncytial virus (RSV) vaccine candidate for older adults
GSK today announced positive headline results from a pre-specified efficacy interim analysis of the AReSVi 006 phase III trial.
Read more -
GSK announces US FDA approval of Priorix for the prevention of measles, mumps and rubella in individuals 12 months of age and older
Priorix becomes an additional source of measles, mumps and rubella vaccine for US patients
Read more -
GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.
Supports development of a strong portfolio of innovative vaccines and specialty medicines
Read more -
GSK unveils latest research advances demonstrating strength of its portfolio and pipeline at ASCO and EHA
Click here for more information about our presence at the ASCO 2022 Annual Meeting.
Read more -
Local budding biologists explore the past, present and future during GSK Science in the Summer™ in partnership with the Franklin Institute
The 2022 curriculum invites elementary school-aged children to play the role of biologists through hands-on activities and experiments.
Read more -
GSK delivers strong Q1 2022 sales of £9.8 billion, +32% AER, +32% CER; Total EPS 35.9p +67% AER, +66% CER and Adjusted EPS 32.8p +43% AER, +43% CER
Sales growth across Pharmaceuticals, Vaccines and Consumer Healthcare driven by strong commercial execution and underlying demand
Read more -
US Food and Drug Administration accepts New Drug Application for daprodustat
US FDA regulatory submission acceptance is the third major regulatory milestone for daprodustat
Read more -
GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9bn
Myelofibrosis is a fatal cancer of the bone marrow impacting the normal production of blood cells
Read more -
New Large-Scale Observational Study Shows COVID-19 Could Create Vulnerability to Shingles for People Age 50+
New Large-Scale Observational Study Shows COVID-19 Could Create Vulnerability to Shingles for People Age 50+
Read more -
ViiV Healthcare announces US FDA approval of Triumeq PD, the first dispersible single tablet regimen containing dolutegravir, a once-daily treatment for children living with HIV
According to UNAIDS, approximately 1.7 million children globally were living with HIV in 2020.
Read more -
ViiV Healthcare announces US FDA approval of Cabenuva for virologically suppressed adolescents living with HIV who are 12 years of age or older and weigh at least 35 kg
This approval marks the first time a long-acting HIV treatment is available for the adolescent population.
Read more -
US Food and Drug Administration revises Emergency Use Authorization for Sotrovimab due to Omicron BA.2 subvariant
The US Food and Drug Administration has amended the Emergency Use Authorization (EUA) Fact Sheet for sotrovimab
Read more -
ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period
US FDA approval of updated label streamlines the initiation process for the first and only complete long-acting HIV treatment.
Read more -
GSK to demonstrate its commitment to improving outcomes for patients with gynecologic cancer at the 2022 SGO Annual Meeting
The meeting will take place in Phoenix, Arizona, and virtually from 18-21 March 2022.
Read more -
Medicago and GSK announce the approval by Health Canada of COVIFENZ®, an adjuvanted plant-based COVID-19 vaccine
A vaccine manufactured in plants and developed in Canada
Read more -
Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine
Sanofi and GSK today announce that they intend to submit data from both their booster and Phase 3 efficacy trials
Read more -
GSK delivers FY 2021 reported sales of £34 billion, stable at AER, +5% CER; Total EPS 87.6p -24% AER, -13% CER and Adjusted EPS of 113.2p -2% AER, +9% CER
GSK delivers FY 2021 reported sales of £34 billion, stable at AER, +5% CER.
Read more
Find out more about us
-
About us
Uniting science, technology and talent to get ahead of disease together
-
Products
We make a wide range of prescription medicines, vaccines and consumer healthcare products.
-
Research and development
Driving scientific innovation to deliver the next generation of transformational medicines and vaccines for patients.
